Related Experiment Video
Updated: May 8, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal Stromal Tumors: A Review
Aakanksha Prasad Asija1, Alex V Mejia, Anthony Prestipino
11Division of Medical Oncology, Department of Internal Medicine and 2Department of Pathology, Thomas Jefferson University Hospital, Philadelphia, PA.
Abstract:
The understanding of aberrant molecular pathways that result in gastrointestinal stromal tumors (GISTs) and the rapid development of molecular therapies that target these pathways represent one of the great milestones in translational oncology. The story of GIST is unique in that targeted molecular therapy was successfully applied in clinical therapeutics, with dramatic results redefining the management of these traditionally chemotherapy-resistant tumors. We briefly review the molecular biology and clinical presentation of GIST and then discuss the adjuvant and neoadjuvant use of tyrosine kinase inhibitors in early-stage GIST and their use in metastatic disease. Newer therapeutic advances in the rapidly changing field of GIST management are also discussed.
Insights
Targeted therapies have revolutionized gastrointestinal stromal tumor (GIST) treatment, offering effective options for traditionally resistant cancers. This review covers molecular pathways, clinical use, and emerging advances in GIST management.
Area of Science:
- Oncology
- Molecular Biology
- Translational Research
Background:
- Gastrointestinal stromal tumors (GISTs) arise from aberrant molecular pathways.
- GISTs are traditionally resistant to chemotherapy.
Purpose of the Study:
- To review the molecular biology and clinical presentation of GIST.
- To discuss the use of tyrosine kinase inhibitors (TKIs) in various stages of GIST.
- To highlight newer therapeutic advances in GIST management.
Main Methods:
- Review of molecular pathways in GIST development.
- Analysis of clinical presentation and management strategies.
- Discussion of adjuvant, neoadjuvant, and metastatic treatment with TKIs.
Main Results:
- Targeted molecular therapy has shown dramatic success in GIST treatment.
- TKIs have redefined the management of GIST, improving outcomes.
- Advances in GIST therapy continue to emerge.
Conclusions:
- Understanding GIST molecular pathways has led to effective targeted therapies.
- Tyrosine kinase inhibitors are crucial in managing GIST across different disease stages.
- The field of GIST therapeutics is rapidly evolving with new advancements.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
02:17The Tumor Microenvironment